Serum response factor neutralizes Purα- and Purβ-mediated repression of the fetal vascular smooth muscle α-actin gene in stressed adult cardiomyocytes

2008 ◽  
Vol 294 (3) ◽  
pp. C702-C714 ◽  
Author(s):  
Aiwen Zhang ◽  
Jason J. David ◽  
Sukanya V. Subramanian ◽  
Xiaoying Liu ◽  
Matthew D. Fuerst ◽  
...  

Mouse hearts subjected to repeated transplant surgery and ischemia-reperfusion injury develop substantial interstitial and perivascular fibrosis that was spatially associated with dysfunctional activation of fetal smooth muscle α-actin (SMαA) gene expression in graft ventricular cardiomyocytes. Compared with cardiac fibroblasts in which nuclear levels of the Sp1 and Smad 2/3 transcriptional-activating proteins increased markedly after transplant injury, the most abundant SMαA gene-activating protein in cardiomyocyte nuclei was serum response factor (SRF). Additionally, cardiac intercalated discs in heart grafts contained substantial deposits of Purα, an mRNA-binding protein and known negative modulator of SRF-activated SMαA gene transcription. Activation of fetal SMαA gene expression in perfusion-isolated adult cardiomyocytes was linked to elevated binding of a novel protein complex consisting of SRF and Purα to a purine-rich DNA element in the SMαA promoter called SPUR, previously shown to be required for induction of SMαA gene transcription in injury-activated myofibroblasts. Increased SRF binding to SPUR DNA plus one of two nearby CArG box consensus elements was observed in SMαA-positive cardiomyocytes in parallel with enhanced Purα:SPUR protein:protein interaction. The data suggest that de novo activation of the normally silent SMαA gene in reprogrammed adult cardiomyocytes is linked to elevated interaction of SRF with fetal-specific CArG and injury-activated SPUR elements in the SMαA promoter as well as the appearance of novel Purα protein complexes in both the nuclear and cytosolic compartments of these cells.

2000 ◽  
Vol 275 (39) ◽  
pp. 30387-30393 ◽  
Author(s):  
Blanca Camoretti-Mercado ◽  
Hong-W. Liu ◽  
Andrew J. Halayko ◽  
Sean M. Forsythe ◽  
John W. Kyle ◽  
...  

1997 ◽  
Vol 17 (4) ◽  
pp. 2266-2278 ◽  
Author(s):  
S Kim ◽  
H S Ip ◽  
M M Lu ◽  
C Clendenin ◽  
M S Parmacek

The SM22alpha promoter has been used as a model system to define the molecular mechanisms that regulate smooth muscle cell (SMC) specific gene expression during mammalian development. The SM22alpha gene is expressed exclusively in vascular and visceral SMCs during postnatal development and is transiently expressed in the heart and somites during embryogenesis. Analysis of the SM22alpha promoter in transgenic mice revealed that 280 bp of 5' flanking sequence is sufficient to restrict expression of the lacZ reporter gene to arterial SMCs and the myotomal component of the somites. DNase I footprint and electrophoretic mobility shift analyses revealed that the SM22alpha promoter contains six nuclear protein binding sites (designated smooth muscle elements [SMEs] -1 to -6, respectively), two of which bind serum response factor (SRF) (SME-1 and SME-4). Mutational analyses demonstrated that a two-nucleotide substitution that selectively eliminates SRF binding to SME-4 decreases SM22alpha promoter activity in arterial SMCs by approximately 90%. Moreover, mutations that abolish binding of SRF to SME-1 and SME-4 or mutations that eliminate each SME-3 binding activity totally abolished SM22alpha promoter activity in the arterial SMCs and somites of transgenic mice. Finally, we have shown that a multimerized copy of SME-4 (bp -190 to -110) when linked to the minimal SM22alpha promoter (bp -90 to +41) is necessary and sufficient to direct high-level transcription in an SMC lineage-restricted fashion. Taken together, these data demonstrate that distinct transcriptional regulatory programs control SM22alpha gene expression in arterial versus visceral SMCs. Moreover, these data are consistent with a model in which combinatorial interactions between SRF and other transcription factors that bind to SME-4 (and that bind directly to SRF) activate transcription of the SM22alpha gene in arterial SMCs.


2008 ◽  
Vol 102 (12) ◽  
pp. 1502-1511 ◽  
Author(s):  
Liisa J. Sundberg-Smith ◽  
Laura A. DiMichele ◽  
Rebecca L. Sayers ◽  
Christopher P. Mack ◽  
Joan M. Taylor

2000 ◽  
Vol 275 (13) ◽  
pp. 9814-9822 ◽  
Author(s):  
Joseph M. Miano ◽  
Michael J. Carlson ◽  
Jeffrey A. Spencer ◽  
Ravi P. Misra

Sign in / Sign up

Export Citation Format

Share Document